Allergy Therapeutics to host KOL webinar on VLP Peanut

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, has announced that it will host a webinar entitled ‘VLP Peanut; a next generation peanut allergy immunotherapy’, on Friday 17 September 2021 at 14.00 BST, 09.00 EDT.

The webinar will include an introduction from Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, and a feature presentation by key opinion leader (KOL), Dr. Mo Shamji, Reader in Immunology & Allergy at Imperial College London.

Dr. Shamji will summarise the findings of the Group’s ex vivo VLP Peanut 001 biomarker study which, as announced on 3 August 2021, showed the hypoallergenic potential of the vaccine candidate, due to enter the clinic in Q1 2022.

Dr. Matt Heath, Principal Scientist at Allergy Therapeutics, will also provide an overview presentation on the Group’s novel virus-like particle (VLP) technology.

The presentation will be followed by a live Q&A session and details can be accessed on the Group’s website at https://www.allergytherapeutics.com/investors/results-reports-and-presentations/. A replay of both will be made available on the website shortly after the event.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million